What the FDA labels say about taking them together
Midazolam and posaconazole
Posaconazole's FDA label of August 3, 2026 names midazolam in its drug interactions section; the midazolam labels PlainMeds reads (4) do not name posaconazole. The posaconazole label: “Discontinuation should be considered in patients who develop abnormal liver tests or monitor liver tests during treatment. Concomitant Use with Midazolam:”
Check it at the source: the midazolam FDA label on DailyMed (effective January 1, 2024, Fresenius Kabi USA, LLC); the posaconazole FDA label on DailyMed (effective August 3, 2026, Aurobindo Pharma Limited).
What does the midazolam label say about posaconazole?
Midazolam's label (effective January 1, 2024) and its 3 other brand-application labels do not name posaconazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Midazolam), Fresenius Kabi USA, LLC, effective January 1, 2024 (SPL set 1cc9ba6e-fa1b-405e-9de8-720c567b2a73), via openFDA; the full label on DailyMed
What does the posaconazole label say about midazolam?
Posaconazole label, drug interactionsMechanism and Clinical Effect (s); Concomitant use of posaconazole with midazolam increased midazolam plasma concentrations which could potentiate and prolong hypnotic and sedative effects [see ].
Posaconazole label, warnings and precautionsDiscontinuation should be considered in patients who develop abnormal liver tests or monitor liver tests during treatment. ( 5.5 ) Concomitant Use with Midazolam:
Noxafil label (Merck Sharp & Dohme LLC, February 13, 2026), warnings and precautionsNoxafil injection should be avoided in patients with moderate or severe renal impairment (eGFR less than 50 mL/min/1.73 m 2 ), unless an assessment of the benefit/risk to the patient justifies the use of Noxafil injection. ( 5.6 , 8.6 ) Concomitant Use with Midazolam:
Source: FDA drug label (Noxafil, NDA022003), Merck Sharp & Dohme LLC, effective February 13, 2026 (SPL set b073b082-7b57-4423-8c06-4fd4263d6f84), via openFDA
Source: FDA drug label (POSACONAZOLE), Aurobindo Pharma Limited, effective August 3, 2026 (SPL set f8a26673-261c-4e8e-b1e1-9e23aaf7f285), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Midazolam | Posaconazole | |
|---|---|---|
| Labeled for | n/a | Fungal infections |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.233 per mL 2 mg/2 mL vial | $2.03 per tablet 100 mg tablet |
| Shortage now | In shortage | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once